Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain Estela Moreno-Martínez; Javier de la Serna-Torraba; Vicente Escudero-Vilaplana; José Ángel Hernández-Rivas; Marina Sánchez-Cuervo; Raquel Sánchez-Hernández;

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain José Ramón González-Porras; Francisco Javier Parrondo García; Eduardo Anguita;

Medicamentos de alto riesgo: programa multidisciplinar para mejorar la seguridad del paciente hospitalizado Maria Dolores Canales-Siguero; Jose Manuel Caro-Teller; Siria Pablos-Bravo; Pedro Pablo Rodríguez-Quesada; Delicias Quintana-Estelles; Pilar Gomis-Muñoz; Angel Tejido-Sanchéz; Jose Miguel Ferrari-Piquero;